Lispro AG Excluded from ESI 2019 Commercial Formulary

Express Scripts has excluded Lilly’s lispro authorized generic (AG) from its 2019 National Preferred Formulary. The exclusion takes effect starting July 1, 2019. Recall, on March 4, 2019, Lilly announced its intention to launch the lispro AG at a 50% WAC discount. Below, FENIX provides brief thoughts on ESI’s exclusion decision.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.